Yesterday’s ASCO SITC presentation provided a 24 months follow-up of the MERECA trial, and our overall impression of the new data is positive, supporting the benefit of adding ilixadencel to sunitinib. With growing confidence in ilixadencel, we are now raising our base case to SEK 17 (14). However, the share price is lower in early trading, suggesting high expectations from investors.